FOXP1 and osteoporosis: Consistent with the in vitro analyses showing that BRD4 loss preserved osteogenesis, administration with JQ-1 reduced Foxp1 levels and slowed the development of a plethora of osteoporosis signs, like poor bone mass, microarchitecture, decreased mineral acquisition, and low mineralized matrix production of bone-marrow mesenchymal cells in methylprednisolone-administered mice.